In a way, because Phase 2a is a pivotal time for a licensing deal with a big pharma, a lot of the holders think that ANP is on the verge of rerating this year.
If a similar deal like Mipomersen with $325m upfront payment after Phase 2a for ATL1103 can happen this year, you can see why the current MC of $23m is always unbelievably low.
In a way, because Phase 2a is a pivotal time for a licensing...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
-0.002(2.44%) |
Mkt cap ! $84.79M | |||
| Open | High | Low | Value | Volume |
| 8.3¢ | 8.3¢ | 7.9¢ | $287.6K | 3.558M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 939854 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 277962 | 1 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |